PremiumThe FlyMorning Movers: U.S. Steel falls after President Biden blocks Nippon deal CytoSorbents reported strong Q4 results, says D. Boral Capital CytoSorbents sees Q4 product revenue $9M-$9.2M vs. $7.35M last year PremiumThe FlyCytoSorbents, Converge Biotech announce strategic partnership CytoSorbents Corporation’s Q3 2024 Financial Highlights CytoSorbents reports Q3 adjusted EPS (8c), consensus (6c) PremiumThe FlyCytoSorbents submits DrugSorb-ATR marketing application to FDA CytoSorbents Announces CFO Transition and New Financial Leadership CytoSorbents appoints Peter Mariani as Chief Financial Officer 
